# To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS

> **NCT05740917** · PHASE1 · UNKNOWN · sponsor: **Xuanzhu Biopharmaceutical Co., Ltd.** · enrollment: 82 (estimated)

## Conditions studied

- AML
- MDS

## Interventions

- **DRUG:** XZB-0004

## Key facts

- **NCT ID:** NCT05740917
- **Lead sponsor:** Xuanzhu Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02
- **Primary completion:** 2023-02
- **Final completion:** 2023-02
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05740917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05740917, "To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05740917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*